In summary, recent advancements in nanotechnology‐enabled vaccine platforms have demonstrated remarkable potential in overcoming critical barriers in cancer immunotherapy by enabling the precise co‐delivery of peptide antigens and STING agonists. Here, STING1 is linked to cancer.